Zobrazeno 1 - 10 of 66 pro vyhledávání: '"Geiger, JL"'
1
Akademický článek
Clinical Utility of Cabozantinib in the Treatment of Locally Advanced or Metastatic Differentiated Thyroid Carcinoma: Patient Selection and Reported Outcomes
Autor: Roof L, Geiger JL
Publikováno v: Cancer Management and Research, Vol Volume 15, Pp 343-350 (2023)
Logan Roof, Jessica L Geiger Department of Hematology & Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USACorrespondence: Jessica L Geiger, Cleveland Clinic Taussig Cancer Institute, 10201 Carnegie Avenue, CA Building CA
Externí odkaz: https://doaj.org/article/72e0a48af4aa435ea543b7ff36ebb527
Zobrazit plný text záznamu
2
Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma
Autor: Geiger, JL, Bauman, JE, Gibson, MK, Gooding, WE, Varadarajan, P, Kotsakis, A, Martin, D, Gutkind, JS, Hedberg, ML, Grandis, JR, Argiris, A
Publikováno v: Head & neck, vol 38, iss 12
Geiger, JL; Bauman, JE; Gibson, MK; Gooding, WE; Varadarajan, P; Kotsakis, A; et al.(2016). Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 38(12), 1759-1764. doi: 10.1002/hed.24501. UC San Francisco: Retrieved from: http://www.escholarship.org/uc/item/3kk8797t
BackgroundPatients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) demonstrate aberrant activation of the phosphotidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway. We examined the efficacy of evero
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::066832df5ae1a9f8afd877ffb41c435b
https://escholarship.org/uc/item/3kk8797t
Zobrazit plný text záznamu
3
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
6
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
7
Akademický článek
T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study.
Autor: Gainor JF; Massachusetts General Hospital, Boston, Massachusetts., Patel MR; Florida Cancer Specialists, Sarasota, Florida.; Sarah Cannon Research Institute, Nashville, Tennessee., Weber JS; Perlmutter Cancer Center at NYU Langone Health, New York, New York., Gutierrez M; Hackensack University Medical Center, Hackensack, New Jersey., Bauman JE; George Washington University Cancer Center, Washington, District of Columbia., Clarke JM; Duke University Medical Center, Durham, North Carolina., Julian R; University of Arizona Cancer Center, Tucson, Arizona., Scott AJ; University of Arizona Cancer Center, Tucson, Arizona., Geiger JL; The Cleveland Clinic Foundation, Cleveland, Ohio., Kirtane K; H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Robert-Tissot C; Moderna, Inc., Cambridge, Massachusetts., Coder B; Moderna, Inc., Cambridge, Massachusetts., Tasneem M; Moderna, Inc., Cambridge, Massachusetts., Sun J; Moderna, Inc., Cambridge, Massachusetts., Zheng W; Moderna, Inc., Cambridge, Massachusetts., Gerbereux L; Moderna, Inc., Cambridge, Massachusetts., Laino A; Moderna, Inc., Cambridge, Massachusetts., Porichis F; Moderna, Inc., Cambridge, Massachusetts., Pollard JR; Moderna, Inc., Cambridge, Massachusetts., Hou P; Moderna, Inc., Cambridge, Massachusetts., Sehgal V; Moderna, Inc., Cambridge, Massachusetts., Chen X; Moderna, Inc., Cambridge, Massachusetts., Morrissey M; Moderna, Inc., Cambridge, Massachusetts., Daghestani HN; Moderna, Inc., Cambridge, Massachusetts., Feldman I; Moderna, Inc., Cambridge, Massachusetts., Srinivasan L; Moderna, Inc., Cambridge, Massachusetts., Frederick JP; Moderna, Inc., Cambridge, Massachusetts., Brown M; Moderna, Inc., Cambridge, Massachusetts., Aanur P; Moderna, Inc., Cambridge, Massachusetts., Meehan R; Moderna, Inc., Cambridge, Massachusetts., Burris HA 3rd; Sarah Cannon Research Institute, Nashville, Tennessee.
Publikováno v: Cancer discovery [Cancer Discov] 2024 Nov 01; Vol. 14 (11), pp. 2209-2223.
Zobrazit plný text záznamu
8
Akademický článek
Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck Cancer.
Autor: Swiecicki PL; Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan Rogel Cancer Center, Ann Arbor, MI., Yilmaz E; Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH., Rosenberg AJ; Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL., Fujisawa T; Head and Neck Medical Oncology, National Cancer Center Hospital East, Chiba, Japan., Bruce JY; University of Wisconsin Carbone Cancer Center, Madison, WI., Meng C; Pfizer, Bothell, WA., Wozniak M; Astellas Pharma, Inc, Northbrook, IL., Zhao Y; Astellas Pharma, Inc, Northbrook, IL., Mihm M; Astellas Pharma, Inc, Northbrook, IL., Kaplan J; Astellas Pharma, Inc, Northbrook, IL., Gorla S; Astellas Pharma, Inc, Northbrook, IL., Geiger JL; Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH.
Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Oct 31, pp. JCO2400646. Date of Electronic Publication: 2024 Oct 31.
Zobrazit plný text záznamu
9
Akademický článek
Evaluating the impact of the degree of extranodal extension on outcomes in locally advanced oral cavity cancer.
Autor: Yalamanchali A; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA., Griffith C; Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA., Reddy CA; Head and Neck Institute, Cleveland Clinic, Cleveland, Ohio, USA., Koyfman SA; Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA., Woody NM; Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA., Campbell SR; Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA., Silver N; Head and Neck Institute, Cleveland Clinic, Cleveland, Ohio, USA., Scharpf J; Head and Neck Institute, Cleveland Clinic, Cleveland, Ohio, USA., Lorenz RR; Head and Neck Institute, Cleveland Clinic, Cleveland, Ohio, USA., Prendes B; Head and Neck Institute, Cleveland Clinic, Cleveland, Ohio, USA., Ku JA; Head and Neck Institute, Cleveland Clinic, Cleveland, Ohio, USA., Lamarre E; Head and Neck Institute, Cleveland Clinic, Cleveland, Ohio, USA., Geiger JL; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Publikováno v: Head & neck [Head Neck] 2024 Sep; Vol. 46 (9), pp. 2340-2347. Date of Electronic Publication: 2024 Apr 25.
Zobrazit plný text záznamu
10
Akademický článek
Intensity-Modulated Reirradiation Therapy With Nivolumab in Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma: A Nonrandomized Controlled Trial.
Autor: Saba NF; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia.; Winship Cancer Institute, Emory University, Atlanta, Georgia., Wong SJ; Department of Medicine, Medical College of Wisconsin, Pleasant Prairie., Nasti T; Winship Cancer Institute, Emory University, Atlanta, Georgia.; The Emory Vaccine Center, Emory University, Atlanta, Georgia., McCook-Veal AA; Winship Cancer Institute, Emory University, Atlanta, Georgia.; Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, Georgia., McDonald MW; Winship Cancer Institute, Emory University, Atlanta, Georgia.; Department of Radiation Oncology, Emory University School of Medicine, Atlanta, Georgia., Stokes WA; Winship Cancer Institute, Emory University, Atlanta, Georgia.; Department of Radiation Oncology, Emory University School of Medicine, Atlanta, Georgia., Anderson AM; Winship Cancer Institute, Emory University, Atlanta, Georgia., Ekpenyong A; Winship Cancer Institute, Emory University, Atlanta, Georgia., Rupji M; Winship Cancer Institute, Emory University, Atlanta, Georgia.; Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, Georgia., Abousaud M; Astellas Pharma Global Development Inc, Northbrook, Illinois., Rudra S; Winship Cancer Institute, Emory University, Atlanta, Georgia.; Department of Radiation Oncology, Emory University School of Medicine, Atlanta, Georgia., Bates JE; Winship Cancer Institute, Emory University, Atlanta, Georgia.; Department of Radiation Oncology, Emory University School of Medicine, Atlanta, Georgia., Remick JS; Winship Cancer Institute, Emory University, Atlanta, Georgia.; Department of Radiation Oncology, Emory University School of Medicine, Atlanta, Georgia., Joshi NP; Department of Radiation Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio., Woody NM; Department of Radiation Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio., Awan M; Department of Medicine, Medical College of Wisconsin, Pleasant Prairie., Geiger JL; Department of Radiation Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio., Shreenivas A; Department of Medicine, Medical College of Wisconsin, Pleasant Prairie., Samsa J; Department of Radiation Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio., Ward MC; Radiation Therapy Center, Atrium Health Levine Cancer Institute, Charlotte, North Carolina., Schmitt NC; Winship Cancer Institute, Emory University, Atlanta, Georgia.; Department of Otolaryngology, Emory University, Atlanta, Georgia., Patel MR; Winship Cancer Institute, Emory University, Atlanta, Georgia.; Department of Otolaryngology, Emory University, Atlanta, Georgia., Higgins KA; Winship Cancer Institute, Emory University, Atlanta, Georgia.; Department of Radiation Oncology, Emory University School of Medicine, Atlanta, Georgia., Teng Y; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia.; Winship Cancer Institute, Emory University, Atlanta, Georgia., Steuer CE; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia.; Winship Cancer Institute, Emory University, Atlanta, Georgia., Shin DM; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia.; Winship Cancer Institute, Emory University, Atlanta, Georgia., Liu Y; Winship Cancer Institute, Emory University, Atlanta, Georgia.; Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, Georgia., Ahmed R; Winship Cancer Institute, Emory University, Atlanta, Georgia.; The Emory Vaccine Center, Emory University, Atlanta, Georgia., Koyfman SA; Department of Radiation Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio.
Publikováno v: JAMA oncology [JAMA Oncol] 2024 Jul 01; Vol. 10 (7), pp. 896-904.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje